Morstyn G, Kinsella T, Hsu S M, Russo A, Gratzner H, Mitchell J
Int J Radiat Oncol Biol Phys. 1984 Aug;10(8):1441-5. doi: 10.1016/0360-3016(84)90365-1.
During a clinical Phase I study of bromodeoxyuridine (BUdR) as a radiation sensitizer we identified the normal and malignant cells that incorporated the BUdR. BUdR was infused for up to 14 days and the in vivo incorporation of BUdR into DNA was assessed using an immunohistochemical technique and a monoclonal antibody directed against BUdR. BUdR was identified in 50% of breast cancer cells and 10% of cells in a malignant melanoma. BUdR was also found in the basal layer of the normal epidermis and in 50% of cells in the marrow. The incorporation of BUdR into cells in the epidermis and marrow may produce the phototoxicity and myelosuppression observed in patients treated with BUdR. Sequential biopsies from a breast cancer taken prior to and following radiotherapy suggested that cells that incorporated BUdR may have been selectively killed by the radiation. The immunohistochemical technique used to identify BUdR appeared to be useful for studies of in vivo and in vitro cell proliferation.
在一项将溴脱氧尿苷（BUdR）作为辐射增敏剂的临床I期研究中，我们鉴定出了摄取了BUdR的正常细胞和恶性细胞。输注BUdR长达14天，并使用免疫组织化学技术和针对BUdR的单克隆抗体评估体内BUdR掺入DNA的情况。在50%的乳腺癌细胞和10%的恶性黑色素瘤细胞中发现了BUdR。在正常表皮的基底层以及50%的骨髓细胞中也发现了BUdR。BUdR掺入表皮和骨髓细胞中可能会导致在用BUdR治疗的患者中观察到的光毒性和骨髓抑制。在放疗前后对乳腺癌进行的连续活检表明，摄取了BUdR的细胞可能已被辐射选择性杀死。用于鉴定BUdR的免疫组织化学技术似乎对体内和体外细胞增殖研究有用。
